465.00
+2.24%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sichuan Kelun-Biotech Biopharmaceutical Co
Its shares trade on HKEX under the ticker 6990.HK. It has been listed since 11 July 2023. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.06bn and a net loss of CN¥382.0m. At that date it held total assets of CN¥5.99bn and shareholders' equity of CN¥4.87bn.
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2023-07-11. Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The firm is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The firm's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Jul 2023
- Employees
- 1,309
- Website
- kelun-biotech.com ↗
Leadership
Pay as last reported
- Mr. Gexin LiuNon-Executive Chairman of the Board
- Mr. Zejian ZhouChief Financial Officer, Joint Company Secretary, since 2022
- Mr. Yi FengSenior Vice President, Deputy General Manager, Chief Strategy Officer
- Dr. Xiangyang TanChief Scientific Officer, Deputy General Manager
- Mr. Junyou GeGeneral Manager, Executive Director, since 2021CN¥3.2m
- Mr. Yong GuoDeputy General Manager, Chief Commercial Officer
- Dr. Xiaoping JinDeputy General Manager, Chief Medical Officer
- Dr. Yiwei ZhangDeputy General Manager
- Dr. Jingyi WangExecutive Director, since 2016CN¥4.2m
- Mr. Ming Fai ChungCompany Secretary
- Mr. Hao FengNon-Executive DirectorCN¥136,000
- Mr. Degui LaiNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sichuan Kelun-Biotech Biopharmaceutical Co Ltd employs 1,309 full-time employees in Chengdu, China.
- The company focuses on biopharmaceuticals, chemical raw materials, and drug formulations for cancer treatment.
- Sichuan Kelun-Biotech Biopharmaceutical Co Ltd has a strong presence in the Chinese biotechnology sector.
Weaknesses
- The company's IPO on 11 July 2023 indicates limited market experience.
- Sichuan Kelun-Biotech Biopharmaceutical Co Ltd has no international presence beyond China.
- The company's product range is limited to specific cancer treatments and non-tumor diseases.
Opportunities
- The Chinese biotechnology sector is growing rapidly with increasing demand for cancer treatments.
- Sichuan Kelun-Biotech Biopharmaceutical Co Ltd can expand its product portfolio in the Health Care industry.
- The company can leverage its Chengdu headquarters for regional growth in Sichuan.
Threats
- The Chinese biotechnology industry faces intense competition from established firms.
- Sichuan Kelun-Biotech Biopharmaceutical Co Ltd must navigate regulatory challenges in the Health Care sector.
- The company's reliance on specific cancer treatments poses market risk if demand shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.